TESTOSTERONE GEL 1% — 25 mg, 50 mg packets; metered-dose pump
📦 Product Snapshot
Use our inquiry form to request official leaflet links, verify common strengths, and ask general authenticity/packaging questions. We do not provide medical advice.
International visitors: our informational support and inquiry form are available to users in the United States, United Kingdom, and Australia.
🧠 Overview
Testosterone gel 1% is a topical formulation of the primary male androgen, approved for testosterone replacement therapy in adult men with confirmed hypogonadism. It provides continuous transdermal delivery of testosterone over 24 hours following a single daily application to intact, clean, dry skin of the shoulders, upper arms, and/or abdomen. Approximately 10% of the applied testosterone dose is absorbed across skin of average permeability during a 24-hour period .
Mechanism of action: Testosterone and its active metabolite dihydrotestosterone (DHT) are responsible for the normal growth and development of male sex organs and maintenance of secondary sex characteristics. These effects include growth and maturation of prostate, seminal vesicles, penis, scrotum; development of male hair distribution; laryngeal enlargement; vocal cord thickening; alterations in body musculature; and fat distribution . Androgens also promote retention of nitrogen, sodium, potassium, phosphorus, and decrease urinary calcium excretion. They stimulate red blood cell production by enhancing erythropoietin production .
Hypogonadism diagnosis: Male hypogonadism results from insufficient secretion of testosterone and is characterized by low serum testosterone concentrations. Symptoms include decreased sexual desire with or without impotence, fatigue and loss of energy, mood depression, regression of secondary sexual characteristics, and osteoporosis . Prior to initiating therapy, diagnosis must be confirmed by measuring morning serum testosterone on at least two separate days with concentrations below the normal range .
Pharmacokinetics: With single daily applications of 50 mg and 100 mg, follow-up measurements confirm that serum testosterone and DHT concentrations are generally maintained within the normal range. Mean steady-state testosterone concentration with 100 mg daily is approximately 612 ng/dL; with 50 mg daily, approximately 365 ng/dL . The skin serves as a reservoir for sustained release. Washing 2 or more hours post-application still maintains testosterone levels within the normal range, but washing earlier lessens levels .
🏷️ Indian Generic Manufacturers & Brand Names
| Indian Manufacturer | Brand Name(s) | Strengths/Formats | Regulatory Approvals / Notes | Source |
|---|---|---|---|---|
| Encube Ethicals Private Limited | Testosterone Gel, 1% (generic) | 50 mg packets, metered-dose pump (12.5 mg/actuation) | US FDA approved (ANDA). DailyMed label updated January 2025. NDC codes: 21922-019-02, 21922-019-47, 21922-019-52 . | |
| Strides Pharma Science Limited | Testosterone Gel 1% (generic) | Unit dose packets | US FDA approved. Distributed by Strides Pharma Inc. Revision 01/2024. Detailed Medication Guide and Instructions for Use available . | |
| Healing Pharma India Pvt Ltd | Testoheal Gel | 5.0 g gel sachets (1% w/w) | Available through pharmacies. | |
| Cheminnova Life Sciences | Androrise Gel | 5.0 g gel tube (1% w/w) | Available through pharmacies. | |
| Kachhela | Testoboon 1% | 80 g bottles (1% w/w) | Indian manufacturer. with export capabilities to US, UK, Australia . | |
| SunPharma (manufacturing in India) | Cernos gel 1% | 50 mg unit-dose sachets | US FDA approved. DailyMed label updated August 2025. Blood pressure increase warning added July 2025 . |
- US FDA Approved Indian Manufacturers: Encube Ethicals, Strides Pharma, Actavis (manufacturing in India) .
- Indian Domestic Market Brands: Testoheal (Healing Pharma), Androrise (Cheminnova Life Sciences), Intas Pharmaceuticals .
- Australian Approved Product: Testogel® (available in 88 g bottles, PBS subsidized as of Jan 2026) .
- International Reference Brands: AndroGel® (US), Testim® (US), Testogel® (Australia/Europe).
- Testosterone gel is a controlled substance (CIII) with generic options available globally.
- Intas Pharmaceuticals exports to US, UK, Australia, Canada, and other markets .
- Australian PBS listing confirms Testogel® 88 g bottles (60 doses) are subsidized .
⚠️ Safety, Side Effects & Monitoring
- Application site reactions: Skin irritation, rash, burning, dryness, pruritus .
- Dermatologic: Acne (most common systemic effect), alopecia .
- Reproductive: Prostatic disorders, abnormal lab tests (PSA elevation), gynecomastia .
- Hematologic: Increased hematocrit, polycythemia .
- Cardiovascular: Edema, hypertension .
- Neurologic: Headache, dizziness, paresthesia .
• Secondary Exposure to Testosterone (boxed warning): Virilization (enlarged penis/clitoris, premature pubic hair, increased erections, aggressive behavior) has been reported in children exposed secondarily. Signs and symptoms regress in most cases with removal of exposure, but enlarged genitalia may not fully return to age-appropriate normal size, and bone age may remain advanced. Women may develop changes in hair distribution, acne, or other signs of virilization. Patients must strictly adhere to instructions: wash hands with soap and water after application, cover application sites with clothing after gel dries, wash site thoroughly prior to skin-to-skin contact, and wash any contact area on others immediately with soap and water .• Venous Thromboembolism (VTE): Deep vein thrombosis (DVT) and pulmonary embolism (PE) have been reported. Evaluate patients with leg pain, edema, warmth, erythema, or acute shortness of breath. Discontinue if suspected .
• Cardiovascular Risk: Some postmarketing studies have shown an increased risk of myocardial infarction and stroke associated with testosterone use. In July 2025, the FDA added a warning for blood pressure increases, recommending periodic blood pressure monitoring .
• Polycythemia: Increased hematocrit may require dose reduction or discontinuation. Check hematocrit prior to initiating, at 3-6 months, and annually thereafter .
• Prostate Risk: Monitor patients with benign prostatic hyperplasia (BPH) for worsening symptoms. Evaluate for prostate cancer prior to initiation and during treatment .
• Edema: Androgens may promote sodium and water retention. Use with caution in patients with preexisting cardiac, renal, or hepatic disease .
• Sleep Apnea: May potentiate sleep apnea, especially in those with risk factors (obesity, chronic lung disease) .
• Hepatotoxicity: Prolonged use of high-dose oral androgens has been associated with peliosis hepatis, hepatic neoplasms, and cholestatic hepatitis. Monitor liver function .
• Spermatogenesis Suppression: Large doses may suppress spermatogenesis via feedback inhibition of pituitary FSH .
• Contraindications: Men with carcinoma of the breast or known/suspected prostate cancer; women who are pregnant (may cause fetal harm) .
• Abuse Potential: Testosterone is a Schedule III controlled substance and has been subject to abuse, typically at doses higher than recommended. Abuse can lead to serious cardiovascular and psychiatric adverse reactions .
- Men with carcinoma of the breast or known or suspected prostate cancer .
- Women who are pregnant. Testosterone may cause fetal harm .
- Hypersensitivity to testosterone or any component of the formulation .
- Insulin and oral antidiabetics: Androgens may decrease blood glucose and insulin requirements. Monitor diabetic patients closely .
- Oral anticoagulants (warfarin): Changes in anticoagulant activity may occur. More frequent monitoring of INR and prothrombin time is recommended .
- Corticosteroids (ACTH, glucocorticoids): Increased risk of fluid retention. Use with caution in patients with cardiac, renal, or hepatic disease .
- Cyclosporine: Androgens may increase cyclosporine levels; monitor for toxicity .
- Pregnancy: Contraindicated. Testosterone can cause virilization of female fetus. Pregnant women must avoid any exposure .
- Lactation: Not indicated for women; excretion in milk unknown.
- Pediatric use: Safety and efficacy not established in males <18 years. Improper use may affect bone growth .
- Geriatric use: Insufficient long-term safety data to assess potential risks of cardiovascular disease and prostate cancer .
- Hepatic impairment: Use with caution; monitor for edema and liver function .
- Renal impairment: Edema may be a complication; monitor closely .
- Starting dose: 50 mg of testosterone (4 pump actuations, two 25 mg packets, or one 50 mg packet) applied once daily in the morning .
- Dose adjustment: Based on total serum testosterone concentration. Can be adjusted to 50 mg, 75 mg, or 100 mg. Titrate based on serum testosterone measured periodically .
- Application sites: Apply to clean, dry, intact skin of shoulders, upper arms, and/or abdomen. Do NOT apply to genitals, chest, armpits (axillae), knees, or back .
- Administration steps:
- Tear open packet at dotted line; squeeze entire contents into palm.
- Apply to application site; allow to dry completely before covering with clothing.
- Wash hands immediately with soap and water after application .
- Avoid showering, swimming, or bathing for at least 5 hours after application .
- Prior to skin-to-skin contact, wash application site thoroughly with soap and water .
- Flammability: Gel is alcohol-based and flammable until dry. Avoid fire, flame, or smoking until gel has dried .
- Storage: Store at room temperature 20°C to 25°C (68°F to 77°F) .
- Symptoms: Exaggerated adverse effects including priapism, edema, polycythemia, and mood changes.
- Management: No specific antidote. Discontinue testosterone gel, provide supportive care, monitor hematocrit and electrolytes. Testosterone is not effectively removed by dialysis .
❓ FAQ
📚 Official References
- DailyMed — TESTOSTERONE GEL, 1% (Encube Ethicals) full prescribing information (updated Jan 2025)
- DailyMed — TESTOSTERONE gel (Actavis) full prescribing information (updated Aug 2025)
- DailyMed — TESTIM (testosterone gel) clinical pharmacology and studies (archived)
- MedLibrary — Testosterone (Strides Pharma) Medication Guide and Instructions for Use (revised Jan 2024)
- FDA — TESTOSTERONE Gel 1% full prescribing information (NIH)
- Healthdirect Australia — Testogel consumer medicine information (PBS updated Jan 2026)
- Farmako — Testoheal Gel (Healing Pharma) product information
- Farmako — Androrise Gel (Cheminnova Life Sciences) product information
- MedLibrary — Testosterone Gel, 1% (Encube Ethicals) warnings and precautions (Page 2)
Submit your review | |
My order was received in great condition! Thank you and I will place another order soon.
Received, thank you,very fast delivery, order again soon Don
My package arrived today as you indicated it would in your.most recent reply. Your professional approach is greatly appreciated, and I will be ordering again later this year.
Thank you kindly, John
Just to let you know that all consignments from my order arrived safely yesterday. Great service as always.
My order was received in the USA within 16 days. Packaged well. I will leave another message after I have used the testosterone gel, cernos gel. So far everything has went very well
Received my product yesterday. Totally pleased with quality and info I received in transit. Will be ordering again.
Tina was very kind.
Thank you.
Will maybe order again!
Wow.
Thank you so much - all items received.
Hello, I am happy to advise that my package arrived today as advertised!
Dear
Arrived in excellent condition.
Thanks a lot,
I will order again soon,
Have a nice day!